Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2024

Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

JNJuliana Navarro-YepesNKNicole M. KettnerXRXiayu Rao

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Navarro-Yepes et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523567https://doi.org/10.1158/0008-5472.27028519.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024
  2. 2Supplemental Figures and Figure Legends from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024
  3. 3Supplemental Figures and Figure Legends from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024
  4. 4Abstract PO3-15-03: Abemaciclib is effective in palbociclib resistant estrogen receptor positive breast cancers2024
  5. 5Data from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024